Cover Image
Market Research Report

Biosimilars Market Access in Psoriasis

Published by Datamonitor Healthcare Product code 498964
Published Content info 24 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biosimilars Market Access in Psoriasis
Published: March 23, 2017 Content info: 24 Pages
Description

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches. Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. This rate of erosion may initially be gradual, as neither physicians nor payers are likely to advocate patient switching.

Table of Contents
Product Code: DMKC0170794

TABLE OF CONTENTS

EXECUTIVE SUMMARY

US

  • Insights and strategic recommendations
  • Inflectra carries biosimilar labeling designation, but is not interchangeable
  • Physicians hesitant to use biosimilars, but understand that payers may hold sway
  • Bibliography

FIVE MAJOR EU MARKETS

  • Insights and strategic recommendations
  • Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
  • Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
  • Payers use biosimilars to pressure originators on pricing
  • Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
  • Biosimilars will be used as price benchmarks for pipeline agents
  • Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
  • Bibliography

METHODOLOGY

  • Primary research

LIST OF TABLES

  • Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Back to Top